Ocular Therapeutix Inc (OCUL) - Product Pipeline Analysis, 2017 Update - Product Image

Ocular Therapeutix Inc (OCUL) - Product Pipeline Analysis, 2017 Update

  • ID: 4372868
  • Company Profile
  • 33 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • Acucela Inc
  • Otonomy Inc
  • Sorrento Therapeutics Inc
  • MORE
Summary

Ocular Therapeutix Inc (Ocular), formerly I-Therapeutix Inc is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for diseases using hydrogel platform technology. The company’s products include DEXTENZA, sustained release travoprost and posterior segment injections. Its hydrogel technology uses polyethylene glycol to create ophthalmic sustained drug delivery systems. Ocular’s hydrogel provides containment, localization and protection from inflammatory response, and a material for sustained delivery of drugs to the eye. The company also provides ReSure Sealant, a ocular sealant proven in clinical trial to be safe in sealing clear corneal incisions following cataract surgery. Its products are used for the treatment of glaucoma and ocular hypertension, post-operative inflammation, allergic conjunctivitis, dry eye and retinal diseases. Ocular is headquartered in Bedford, Massachusetts, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Ocular Therapeutix Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Acucela Inc
  • Otonomy Inc
  • Sorrento Therapeutics Inc
  • MORE
  • Ocular Therapeutix Inc Company Overview
  • Ocular Therapeutix Inc Company Snapshot
  • Ocular Therapeutix Inc Pipeline Products and Ongoing Clinical Trials Overview
  • Ocular Therapeutix Inc - Pipeline Analysis Overview
  • Ocular Therapeutix Inc - Key Facts
  • Ocular Therapeutix Inc - Major Products and Services
  • Ocular Therapeutix Inc Pipeline Products by Development Stage
  • Ocular Therapeutix Inc Ongoing Clinical Trials by Trial Status
  • Ocular Therapeutix Inc Pipeline Products Overview
  • DEXTENZA
  • DEXTENZA Product Overview
  • Injectable Hydrogel Slurry - anti-VEGF
  • Injectable Hydrogel Slurry - anti-VEGF Product Overview
  • Moxifloxacin Punctum Plug
  • Moxifloxacin Punctum Plug Product Overview
  • OTX-TP
  • OTX-TP Product Overview
  • OTX-TP Clinical Trial
  • Ocular Therapeutix Inc - Key Competitors
  • Ocular Therapeutix Inc - Key Employees
  • Ocular Therapeutix Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Recent Developments
  • Ocular Therapeutix Inc, Recent Developments
  • Jun 26, 2017: Ocular Therapeutix Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
  • Jun 22, 2017: Ocular Therapeutix Announces Executive Transition Plans
  • May 11, 2017: Ocular Therapeutix Presented Phase 3 Data for DEXTENZA at the Association for Research in Vision and Ophthalmology Annual Meeting
  • May 05, 2017: Ocular Therapeutix Reports First Quarter 2017 Financial Results
  • May 02, 2017: Ocular Therapeutix Announces Presentation on ReSure Sealant at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
  • May 02, 2017: Ocular Therapeutix to Present Data on OTX-TP (travoprost insert) at the Association for Research in Vision and Ophthalmology Annual Meeting
  • May 02, 2017: Ocular Therapeutix Announces Data on DEXTENZA at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
  • Apr 06, 2017: Ocular Therapeutix Appoints George Migausky as Interim Chief Financial Officer
  • Mar 15, 2017: New Publication Describes Positive Patient Experience in Study of Ocular Therapeutix’ DEXTENZA Following Cataract Surgery
  • Mar 10, 2017: Ocular Therapeutix Reports Fourth Quarter and Full Year 2016 Financial Results
  • Appendix
  • Methodology
  • About
  • Contact
  • Disclaimer
List of Tables
  • Ocular Therapeutix Inc Pipeline Products and Ongoing Clinical Trials Overview
  • Ocular Therapeutix Inc Pipeline Products by Equipment Type
  • Ocular Therapeutix Inc Pipeline Products by Indication
  • Ocular Therapeutix Inc Ongoing Clinical Trials by Trial Status
  • Ocular Therapeutix Inc, Key Facts
  • Ocular Therapeutix Inc, Major Products and Services
  • Ocular Therapeutix Inc Number of Pipeline Products by Development Stage
  • Ocular Therapeutix Inc Pipeline Products Summary by Development Stage
  • Ocular Therapeutix Inc Ongoing Clinical Trials by Trial Status
  • Ocular Therapeutix Inc Ongoing Clinical Trials Summary
  • DEXTENZA - Product Status
  • DEXTENZA - Product Description
  • Injectable Hydrogel Slurry - anti-VEGF - Product Status
  • Injectable Hydrogel Slurry - anti-VEGF - Product Description
  • Moxifloxacin Punctum Plug - Product Status
  • Moxifloxacin Punctum Plug - Product Description
  • OTX-TP - Product Status
  • OTX-TP - Product Description
  • OTX-TP - Non-significant Risk Feasibility Study to Assess Retention and Replacement of the OTX Punctum Plug
  • Ocular Therapeutix Inc, Key Employees
  • Ocular Therapeutix Inc, Other Locations
  • Glossary
List of Figures
  • Ocular Therapeutix Inc Pipeline Products by Equipment Type
  • Ocular Therapeutix Inc Pipeline Products by Development Stage
  • Ocular Therapeutix Inc Ongoing Clinical Trials by Trial Status
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Sorrento Therapeutics Inc
  • Otonomy Inc
  • Neurocrine Biosciences Inc
  • Acucela Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll